Open AccessSafety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212)
Author(s) -
Emily Greengard,
Yaël P. Mossé,
Xiaowei Liu,
Charles G. Minard,
Joel M. Reid,
Stephan D. Voss,
Keith D. Wilner,
Elizabeth Fox,
Frank M. Balis,
Susan M. Blaney,
Peter C. Adamson,
Brenda Weigel
Publication year - 2020
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-020-04171-4
Subject(s) - crizotinib , medicine , tolerability , pharmacokinetics , pharmacology , oncology , cyclophosphamide , chemotherapy , topotecan , adverse effect , lung cancer , malignant pleural effusion
This phase 1 study aimed to determine the safety, tolerability and recommended phase 2 dose (RP2D) of crizotinib in combination with cytotoxic chemotherapy for children with refractory solid tumors and ALCL.